Nitric Oxide (NO) and Endothelial Dysfunction in Women With PTSD

NCT07485231 | Not Yet Recruiting

• 1 other identifier: PT-2025-34371
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This research study is conducted to better understand why women with post-traumatic stress disorder (PTSD) have higher risk of cardiovascular disease as they get older. This study looks at how trauma and PTSD affect blood vessels in young women by testing whether the dietary supplement beetroot juice might help improve the function of blood vessels in women suffering from PTSD.

Conditions

Post Traumatic Stress Disorder; Trauma

Outcome Measures

Primary Outcomes (1)

• Change in Flow Mediated Dilation (FMD)

  Difference in FMD before and after beetroot juice administration

  Month 2

Study Arms (2)

Beetroot Juice

EXPERIMENTAL

Dietary Supplement: Beetroot Juice

Placebo Juice

PLACEBO COMPARATOR

Dietary Supplement: Placebo Juice

Interventions

Beetroot Juice DIETARY_SUPPLEMENT

We will use James White Beet It sports shot (70ml), which contains 400 mg of dietary nitrate

Beetroot Juice

Placebo Juice DIETARY_SUPPLEMENT

James White Nitrate Depleted Placebo ( 70 ml) will be used as a placebo

Placebo Juice

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Women ages 18-40 (female as defined biologically)
• Premenopausal as indicated by self-report of menstrual cycles.
• Trauma-exposed with or without PTSD. Diagnostic Criteria for both trauma exposure and PTSD will be obtained via clinical interview, medical records, and self-report.
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Diagnosis of major depression (MD).
• Comorbid Psychiatric Conditions: Participants with other anxiety disorders, and bipolar disorder without psychotic features, mild to moderate traumatic brain injury, and borderline personality disorder will be included.
• Medical records will also assist in the detection of current and lifetime comorbid psychiatric conditions.
• Any over-the-counter medications must be held for 24 hours before each testing visit.
• The PTSD groups must meet DSM-5 diagnostic criteria for PTSD assessed via the CAPS 5 (at least 6 symptoms: 1 B, 1 C, 2 D, and 2 E), with a total severity score of ≥25:
• We will enroll participants as long as they are stable on meds (no changes within the past 3 months). Many participants are often on psychiatric meds, but still have PTSD symptoms. It really isn't that this is an untreated sample. It is more than that it includes people actively symptomatic, regardless of current treatment. Participants will not be required to stop any psychiatric medications.

You may not qualify if:

• Non-biologically female people who may otherwise identify as women
• Individuals who are taking hormone replacement therapy.
• Pregnant, breastfeeding, or planning to become pregnant during the duration of the study
• Individuals taking any types of hormonal contraceptives.
• Self-reported Medical conditions: hypertension, diabetes, heart disease, vascular disease, ongoing illicit drug use, excessive alcohol use (\>2 drinks per day), hyperlipidemia, autonomic dysfunction, any serious systemic disease, gastrointestinal disorders
• Medications for PTSD or other cardiovascular diseases or any medication known to affect vascular function and central sympathetic output, such as antihypertensive medications (beta blockers, calcium channel blockers, angiotensin receptor blockers, angiotensin receptor inhibitors), corticosteroids, direct-acting vasodilators like nitrates and hydralazine, thyroid medications such as carbimazole, thyroxin.
• Psychiatric Comorbidities: Ongoing substance abuse will be excluded because of the sympathoexcitatory effect of illicit drugs such as cocaine and methamphetamines that exert a powerful pressor and direct sympathoexcitatory effect. A report of a minimum of 6 months of non-drug use (recovery) will be required for those who have a history of illicit drug use
• Psychotic and dissociative disorders will be excluded due to concerns regarding comprehension and adherence.
• The inability or unwillingness to abstain from nicotine use for at least 12 hours prior to physiologic studies (visits 1 and 2), to eliminate sympathoexcitatory effects of nicotine (half-life of 2 hours).
• Any gastrointestinal complications, such as irritable bowel syndrome, and diseases such as celiac disease, irritable bowel syndrome. Any food allergy related to dietary nitrates. Any food allergy to nitrate-containing foods.

Sponsors & Collaborators

• University of Minnesota: lead

Study Sites (1)

University of Minnesota

Minneapolis, Minnesota, 55455, United States

Location

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic; Wounds and Injuries

Condition Hierarchy (Ancestors)

Stress Disorders, Traumatic; Trauma and Stressor Related Disorders; Mental Disorders

Study Officials

• Ida-Arlaine Fonkoue, MD, PhD, MsCR

  University of Minnesota

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ida-Arlaine Fonkoue, MD, PhD, MsCR

CONTACT

612-626-2520; fonko001@umn.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 16, 2026
• First Posted: March 20, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): May 1, 2028
• Study Completion (Estimated): May 1, 2028
• Last Updated: March 20, 2026

Record last verified: 2026-03

Locations

US (1)